Our open label, prospective, randomized (pairwise) and controlled study aims to investigate the effect of the semaglutide, a once-weekly injection GLP-1 RA, addition to standard of care weight loss intervention (personalized life style and exercise) in obese older (≥65 years) subjects for 16 weeks on body weight and composition, muscle strength, the expression of lipolytic and thermogenic genes and mitochondrial respiration in subcutaneous white adipose tissue. This will be compared to outcomes from an age, gender and BMI matched group managed with standard care protocol alone. We anticipate that such weigh loss treatment will not only achieve significant weight loss but will also significantly improve lean to fat mass ratio and potentially increase muscle strength.
Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email email@example.com and someone will assist you.
Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided in the aforementioned ways, please contact firstname.lastname@example.org.